- Home
- STIM vs EDIT Comparison
STIM vs EDIT Comparison
Compare STIM & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STIM
- EDIT
- Stock Information
- Founded
- STIM 2003
- EDIT 2013
- Country
- STIM United States
- EDIT United States
- Employees
- STIM N/A
- EDIT N/A
- Industry
- STIM Medical/Dental Instruments
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STIM Health Care
- EDIT Health Care
- Exchange
- STIM Nasdaq
- EDIT Nasdaq
- Market Cap
- STIM 224.8M
- EDIT 263.7M
- IPO Year
- STIM 2018
- EDIT 2016
- Fundamental
- Price
- STIM $3.36
- EDIT $2.67
- Analyst Decision
- STIM Strong Buy
- EDIT Buy
- Analyst Count
- STIM 2
- EDIT 12
- Target Price
- STIM $7.00
- EDIT $5.40
- AVG Volume (30 Days)
- STIM 1.5M
- EDIT 1.8M
- Earning Date
- STIM 08-05-2025
- EDIT 08-12-2025
- Dividend Yield
- STIM N/A
- EDIT N/A
- EPS Growth
- STIM N/A
- EDIT N/A
- EPS
- STIM N/A
- EDIT N/A
- Revenue
- STIM $111,106,000.00
- EDIT $38,901,000.00
- Revenue This Year
- STIM $105.22
- EDIT N/A
- Revenue Next Year
- STIM $11.89
- EDIT N/A
- P/E Ratio
- STIM N/A
- EDIT N/A
- Revenue Growth
- STIM 54.17
- EDIT N/A
- 52 Week Low
- STIM $0.52
- EDIT $0.91
- 52 Week High
- STIM $5.92
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- STIM 39.34
- EDIT 49.68
- Support Level
- STIM $3.13
- EDIT $2.66
- Resistance Level
- STIM $3.51
- EDIT $2.92
- Average True Range (ATR)
- STIM 0.29
- EDIT 0.23
- MACD
- STIM -0.06
- EDIT -0.00
- Stochastic Oscillator
- STIM 19.49
- EDIT 54.55
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.